Analysts expect C.R. Bard, Inc. (NYSE:BCR) to post earnings of $2.95 per share for the current fiscal quarter, Zacks reports. Eight analysts have issued estimates for C.R. Bard’s earnings, with the highest EPS estimate coming in at $3.02 and the lowest estimate coming in at $2.89. C.R. Bard posted earnings of $2.64 per share during the same quarter last year, which suggests a positive year-over-year growth rate of 11.7%. The business is expected to report its next quarterly earnings report on Tuesday, October 24th.

According to Zacks, analysts expect that C.R. Bard will report full year earnings of $11.83 per share for the current fiscal year, with EPS estimates ranging from $11.78 to $11.96. For the next financial year, analysts forecast that the company will report earnings of $12.93 per share, with EPS estimates ranging from $12.49 to $13.15. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow C.R. Bard.

C.R. Bard (NYSE:BCR) last announced its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, beating analysts’ consensus estimates of $2.84 by $0.08. The firm had revenue of $979.70 million during the quarter, compared to analysts’ expectations of $976.53 million. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter last year, the company posted $2.54 earnings per share.

A number of equities analysts have issued reports on BCR shares. BidaskClub raised shares of C.R. Bard from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 8th. BMO Capital Markets reaffirmed a “hold” rating and set a $317.00 price objective on shares of C.R. Bard in a report on Tuesday, July 11th. Zacks Investment Research downgraded shares of C.R. Bard from a “buy” rating to a “hold” rating in a report on Monday, July 17th. Finally, Jefferies Group LLC reaffirmed a “hold” rating on shares of C.R. Bard in a report on Thursday, August 3rd. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $292.00.

In related news, insider Timothy P. Collins sold 55,818 shares of the business’s stock in a transaction dated Thursday, October 12th. The shares were sold at an average price of $322.03, for a total value of $17,975,070.54. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Sharon M. Luboff sold 30,252 shares of the business’s stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $320.00, for a total transaction of $9,680,640.00. The disclosure for this sale can be found here. Insiders have sold a total of 118,145 shares of company stock worth $37,906,404 over the last ninety days. Insiders own 0.80% of the company’s stock.

Several large investors have recently modified their holdings of BCR. BlackRock Inc. boosted its holdings in shares of C.R. Bard by 1,365.7% in the 1st quarter. BlackRock Inc. now owns 7,398,081 shares of the medical instruments supplier’s stock worth $1,838,719,000 after buying an additional 6,893,346 shares during the last quarter. Farallon Capital Management LLC purchased a new position in shares of C.R. Bard in the 2nd quarter worth about $463,101,000. Alpine Associates Management Inc. purchased a new position in shares of C.R. Bard in the 2nd quarter worth about $265,663,000. MARSHALL WACE ASIA Ltd purchased a new position in shares of C.R. Bard in the 1st quarter worth about $132,062,000. Finally, Marshall Wace North America L.P. purchased a new position in shares of C.R. Bard in the 1st quarter worth about $132,062,000. 79.22% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This news story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/18/c-r-bard-inc-bcr-expected-to-announce-earnings-of-2-95-per-share.html.

Shares of C.R. Bard (NYSE BCR) traded up 0.73% during mid-day trading on Friday, reaching $326.91. 355,533 shares of the company’s stock were exchanged. The company has a market cap of $23.76 billion, a PE ratio of 42.92 and a beta of 0.58. The company’s 50-day moving average price is $320.43 and its 200 day moving average price is $308.46. C.R. Bard has a 52-week low of $203.63 and a 52-week high of $326.92.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be issued a dividend of $0.26 per share. This represents a $1.04 dividend on an annualized basis and a yield of 0.32%. The ex-dividend date is Thursday, December 7th. C.R. Bard’s dividend payout ratio is 13.67%.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Get a free copy of the Zacks research report on C.R. Bard (BCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for C.R. Bard (NYSE:BCR)

Receive News & Stock Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related stocks with our FREE daily email newsletter.